Terms: = Pancreatic cancer AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Clinical Outcome
4 results:
1. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract] [Full Text] [Related]
2. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract] [Full Text] [Related]
3. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy.
Nakamura A; Horinouchi M; Goto M; Nagata K; Sakoda K; Takao S; Imai K; Kim YS; Sato E; Yonezawa S
J Pathol; 2002 Jun; 197(2):201-10. PubMed ID: 12015744
[TBL] [Abstract] [Full Text] [Related]
4. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy.
Nio Y; Dong M; Iguchi C; Yamasawa K; Toga T; Itakura M; Tamura K
J Surg Oncol; 2001 Mar; 76(3):188-96. PubMed ID: 11276023
[TBL] [Abstract] [Full Text] [Related]
